Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors
Open Access
- 6 January 2023
- journal article
- research article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (3), bvad002
- https://doi.org/10.1210/jendso/bvad002
Abstract
Context The occurrence of multiple endocrinopathies due to immune checkpoint inhibitors (ICIs) is relatively common as an adverse event. However, the occurrence of a combination of hypophysitis and type 1 diabetes mellitus (T1DM) is extremely rare, and its clinical features are unclear. Objective To comparatively analyze the clinical features of this combination and each individual ICI-induced endocrinopathy. Methods We reported three cases that we encountered and reviewed previously reported cases of patients with combined hypophysitis and T1DM due to ICIs. Results Anti-programmed cell death-1 (anti-PD-1) antibodies were prescribed to all the three cases. The duration from ICI initiation to the onset of these endocrine disease was 12–48 weeks. Several human leukocyte antigen (HLA) haplotypes that have disease susceptibility to hypophysitis were detected in all three patients. Combining the 17 previously reported cases, combined endocrinopathies were more common in men (85%). The onset age was 60 s for both combined and single endocrinopathies. Anti-PD-1 antibodies were used in most of the cases (90%). The time from ICI initiation to the onset of endocrinopathies was 24 [8-76] weeks for hypophysitis and 32 [8-76] weeks for T1DM in patients with combined endocrinopathies, which was not significantly different from that for each single endocrinopathy. Conclusions We presented three cases of patients with combined endocrinopathies of hypophysitis and T1DM that may have been caused by anti-PD-1 antibodies. There was no difference in the time from ICI initiation to the onset of endocrinopathies between combined and single endocrinopathies. Further case accumulation and pathogenic investigations are required.Funding Information
- JSPS KAKENHI (15K09432, 22K08654, 21K10474)
This publication has 41 references indexed in Scilit:
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic MelanomaJournal of Clinical Endocrinology & Metabolism, 2014
- Ipilimumab-induced autoimmune adrenalitisThe Lancet Diabetes & Endocrinology, 2013
- Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute‐onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012)Journal of Diabetes Investigation, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetesJournal of Diabetes Investigation, 2011
- Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onsetDiabetologia, 2009
- Molecular amino acid signatures in the MHC class II peptide-binding pocket predispose to autoimmune thyroiditis in humans and in miceProceedings of the National Academy of Sciences of the United States of America, 2008
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and HypophysitisJournal of Immunotherapy, 2007
- Isolated corticotrophin deficiencyPituitary, 2006
- The Association ofCTLA4Polymorphism with Type 1 Diabetes Is Concentrated in Patients Complicated with Autoimmune Thyroid Disease: A Multicenter Collaborative Study in JapanJournal of Clinical Endocrinology & Metabolism, 2006